UMIs are introduced in many NGS experiments such as RNA-seq, single-cell RNA-seq (scRNA-seq) (Zilionis et al., 2017; Srivastava et al., 2019), BCR repertoire sequencing (Egorov et al., 2015), etc. Also, it is worth noting that the UMI approach is suitable for NGS-based measurable residual disease detection, which allows the determination of individual risk in acute myeloid leukemia patients based on mutational clearance after treatment (Yoest et al., 2020) and the IG/TR rearrangements in acute lymphoblastic leukemia (Bruggemann et al., 2019). This evidence concerns the gene BCR and acute myeloid leukemia.